I-SPY 2 TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer (I-SPY 2)

Clinical Trial ID NCT01042379

PubWeight™ 63.53‹?›

🔗 Visit the ClinicalTrials.gov page for NCT01042379

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Modulation of oxidative stress as an anticancer strategy. Nat Rev Drug Discov 2013 4.72
2 Treatment of HER2-positive breast cancer: current status and future perspectives. Nat Rev Clin Oncol 2011 4.12
3 Tumour heterogeneity in the clinic. Nature 2013 3.92
4 Combinatorial drug therapy for cancer in the post-genomic era. Nat Biotechnol 2012 3.10
5 Adaptive Randomization of Neratinib in Early Breast Cancer. N Engl J Med 2016 2.40
6 Adaptive Randomization of Veliparib-Carboplatin Treatment in Breast Cancer. N Engl J Med 2016 2.37
7 Adaptive clinical trials in oncology. Nat Rev Clin Oncol 2011 2.06
8 Harnessing synthetic lethal interactions in anticancer drug discovery. Nat Rev Drug Discov 2011 2.01
9 Antibody-based therapeutics to watch in 2011. MAbs 2011 2.00
10 Lung Master Protocol (Lung-MAP)-A Biomarker-Driven Protocol for Accelerating Development of Therapies for Squamous Cell Lung Cancer: SWOG S1400. Clin Cancer Res 2015 1.35
11 Treating breast cancer in the 21st century: emerging biological therapies. J Cancer 2013 1.26
12 Reverse phase protein microarrays advance to use in clinical trials. Mol Oncol 2010 1.23
13 Can we unlock the potential of IGF-1R inhibition in cancer therapy? Cancer Treat Rev 2014 1.16
14 Targeting DNA damage response in cancer therapy. Cancer Sci 2014 1.16
15 The ethical use of mandatory research biopsies. Nat Rev Clin Oncol 2011 1.11
16 Accelerating identification and regulatory approval of investigational cancer drugs. JAMA 2011 1.10
17 Pharmacogenomics in clinical practice and drug development. Nat Biotechnol 2012 1.08
18 Leveling the playing field: bringing development of biomarkers and molecular diagnostics up to the standards for drug development. Clin Cancer Res 2012 1.07
19 Treatment options for patients with triple-negative breast cancer. J Hematol Oncol 2010 1.07
20 Triple negative breast cancer: looking for the missing link between biology and treatments. Oncotarget 2015 1.03
21 Metabolic roles of AMPK and metformin in cancer cells. Mol Cells 2013 1.02
22 The Brave New World of clinical cancer research: Adaptive biomarker-driven trials integrating clinical practice with clinical research. Mol Oncol 2015 1.01
23 Reports from the 2010 Clinical and Translational Cancer Research Think Tank meeting: design strategies for personalized therapy trials. Clin Cancer Res 2012 1.01
24 Better therapeutic trials in ovarian cancer. J Natl Cancer Inst 2014 1.00
25 Lung cancer in the era of precision medicine. Clin Cancer Res 2015 0.96
26 Human epidermal growth factor receptor family-targeted therapies in the treatment of HER2-overexpressing breast cancer. Oncologist 2014 0.89
27 Poly(Adenosine diphosphate-ribose) polymerase inhibitors in cancer treatment. Hematol Oncol Clin North Am 2012 0.88
28 Triple-negative breast cancer: an update on neoadjuvant clinical trials. Int J Breast Cancer 2012 0.86
29 Recent advances in the development of anti-HER2 antibodies and antibody-drug conjugates. Ann Transl Med 2014 0.86
30 Reverse phase protein arrays: mapping the path towards personalized medicine. Mol Diagn Ther 2014 0.85
31 Trial Watch-Small molecules targeting the immunological tumor microenvironment for cancer therapy. Oncoimmunology 2016 0.84
32 Ganetespib: research and clinical development. Onco Targets Ther 2015 0.83
33 Current Status of Poly(ADP-ribose) Polymerase Inhibitors as Novel Therapeutic Agents for Triple-Negative Breast Cancer. Int J Breast Cancer 2011 0.82
34 A review of phase II trial designs for initial marker validation. Contemp Clin Trials 2013 0.80
35 Emerging therapeutic targets in metastatic progression: A focus on breast cancer. Pharmacol Ther 2016 0.79
36 Modulation of insulin-like growth factor-1 receptor and its signaling network for the treatment of cancer: current status and future perspectives. Oncol Rev 2013 0.79
37 Creative trial design in RA: optimizing patient outcomes. Nat Rev Rheumatol 2013 0.78
38 Approaches to modernize the combination drug development paradigm. Genome Med 2016 0.77
39 Inhibition of the angiopoietin/Tie2 axis induces immunogenic modulation, which sensitizes human tumor cells to immune attack. J Immunother Cancer 2015 0.77
40 Precision Oncology Medicine: The Clinical Relevance of Patient-Specific Biomarkers Used to Optimize Cancer Treatment. J Clin Pharmacol 2016 0.77
41 Next-Generation Sequencing to Guide Clinical Trials. Clin Cancer Res 2015 0.76
42 Biomarker-Guided Adaptive Trial Designs in Phase II and Phase III: A Methodological Review. PLoS One 2016 0.76
43 Angiotensin Converting Enzyme Inhibitors (ACEI) and doxorubicin pharmacokinetics in women receiving adjuvant breast cancer treatment. Springerplus 2015 0.76
44 Neratinib shows efficacy in the treatment of HER2 amplified carcinosarcoma in vitro and in vivo. Gynecol Oncol 2015 0.75
45 Hsp90 Inhibition Results in Glucocorticoid Receptor Degradation in Association with Increased Sensitivity to Paclitaxel in Triple-Negative Breast Cancer. Horm Cancer 2016 0.75
46 Patterns in target-directed breast cancer research. Springerplus 2016 0.75
47 Precision medicine clinical trials: defining new treatment strategies. Semin Oncol Nurs 2014 0.75
48 Targeting translation initiation in breast cancer. Translation (Austin) 2014 0.75
49 Exploratory Cost-Effectiveness Analysis of Response-Guided Neoadjuvant Chemotherapy for Hormone Positive Breast Cancer Patients. PLoS One 2016 0.75
50 Dual HER2 blockade in the neoadjuvant and adjuvant treatment of HER2-positive breast cancer. Breast Cancer (Dove Med Press) 2015 0.75
51 Targeted therapy in cancer. Cancer Chemother Pharmacol 2015 0.75
52 CCR 20th Anniversary Commentary: Simpson's Paradox and Neoadjuvant Trials. Clin Cancer Res 2015 0.75
Next 100